514 Change of laboratory parameters during anti-PD1 treatment in patients with melanoma

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.

Treatment with fully human monoclonal antibodies against programmed death 1 (PD1) receptor has shown great promise for a number of advanced malignancies. Although inflammatory adverse events have been well described with anti-CTL antigen 4 (CTLA4) therapy, experience with the range of adverse effects of anti-PD1 remains comparatively limited. Here, we report on a patient with advanced mucosal m...

متن کامل

Therapeutic Drug Monitoring of Sirolimus,Correlation With Laboratory Parameters In Transplant Patients

Sirolimus is a potent immunosuppressive agent administered as prophylactic agent to prevent rejection after organ transplantation. Sirolimus must be used within a narrow therapeutic window. Due to inter- and intra-variability, sirolimus blood concentrations may be affected, therefore, there is no possibility of predicting the sirolimus blood concentrations based on the dose patients received. T...

متن کامل

Clinical and Laboratory Findings in Patients with Tramadol Intoxication Referred to Razi Hospital During 2005-06

ABSTRACT Introduction: Frequency of Tramadol intoxication is increasing as a result of its use as a drug for suppression of withdrawal symptoms by opioids abusers and its wide accessibility of this drug. Tramadol intoxication can lead to death and, therefore, early identification of its clinical manifestations is crucial since early detection of the intoxication and its treatment could impro...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Investigative Dermatology

سال: 2019

ISSN: 0022-202X

DOI: 10.1016/j.jid.2019.07.564